Pharmaceutical industry news
Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.
41,170 stories, page 442 of 687
🇺🇸Industryjnj.comTier 1 · Company source
TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma
· Investigational MonumenTAL-6 trial is the first and only Phase 3 study of a dual antigen, BCMA and...
Johnson & Johnson NewsOriginal source






